Jefferies Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $13.3K | Sell |
50
-57,549
| -100% | -$12.2M | ﹤0.01% | 1553 |
|
|
2022
Q2 | $11.7M | Buy |
57,599
+32,760
| +132% | +$6.7M | 0.1% | 154 |
|
|
2022
Q1 | $5.23M | Sell |
24,839
-39,059
| -61% | -$8.49M | 0.03% | 405 |
|
|
2021
Q4 | $15.3M | Buy |
63,898
+54,541
| +583% | +$14M | 0.09% | 186 |
|
|
2021
Q3 | $2.65M | Sell |
9,357
-7,306
| -44% | -$2.39M | 0.02% | 659 |
|
|
2021
Q2 | $5.77M | Sell |
16,663
-55,843
| -77% | -$16.9M | 0.04% | 422 |
|
|
2021
Q1 | $20.3M | Buy |
72,506
+68,854
| +1,885% | +$18.6M | 0.18% | 91 |
|
|
2020
Q4 | $894K | Sell |
3,652
-98
| -3% | -$25.3K | 0.01% | 978 |
|
|
2020
Q3 | $1.06M | Hold |
3,750
| – | – | 0.01% | 778 |
|
|
2020
Q2 | $1K | Sell |
3,750
-14,667
| -80% | -$4.41M | 0.01% | 756 |
|
|
2020
Q1 | $5.83M | Sell |
18,417
-58,750
| -76% | -$17.8M | 0.06% | 270 |
|
|
2019
Q4 | $22.9M | Buy |
77,167
+41,019
| +113% | +$11.4M | 0.18% | 93 |
|
|
2019
Q3 | $8.42M | Sell |
36,148
-1,163
| -3% | -$271K | 0.07% | 279 |
|
|
2019
Q2 | $8.73M | Buy |
37,311
+20,727
| +125% | +$4.79M | 0.06% | 263 |
|
|
2019
Q1 | $3.92M | Buy |
16,584
+14,977
| +932% | +$4.72M | 0.03% | 540 |
|
|
2018
Q4 | $484K | Sell |
1,607
-19,364
| -92% | -$6.18M | ﹤0.01% | 1471 |
|
|
2018
Q3 | $7.41M | Buy |
20,971
+13,907
| +197% | +$4.79M | 0.05% | 375 |
|
|
2018
Q2 | $2.05M | Sell |
7,064
-4,607
| -39% | -$1.3M | 0.01% | 878 |
|
|
2018
Q1 | $3.2M | Buy |
11,671
+8,558
| +275% | +$2.66M | 0.02% | 654 |
|
|
2017
Q4 | $992K | Sell |
3,113
-18,617
| -86% | -$5.97M | ﹤0.01% | 1373 |
|
|
2017
Q3 | $6.8M | Sell |
21,730
-46,936
| -68% | -$13.9M | 0.04% | 407 |
|
|
2017
Q2 | $18.6M | Buy |
68,666
+52,434
| +323% | +$13.9M | 0.12% | 143 |
|
|
2017
Q1 | $4.44M | Sell |
16,232
-15,862
| -49% | -$4.48M | 0.03% | 548 |
|
|
2016
Q4 | $9.1M | Sell |
32,094
-100,031
| -76% | -$29.7M | 0.05% | 372 |
|
|
2016
Q3 | $41.4M | Buy |
132,125
+124,243
| +1,576% | +$36.8M | 0.21% | 72 |
|
|
2016
Q2 | $1.91M | Buy |
7,882
+5,399
| +217% | +$1.42M | 0.01% | 878 |
|
|
2016
Q1 | $646K | Sell |
2,483
-24,616
| -91% | -$6.5M | ﹤0.01% | 1325 |
|
|
2015
Q4 | $8.3M | Sell |
27,099
-11,184
| -29% | -$3.21M | 0.05% | 315 |
|
|
2015
Q3 | $11.2M | Buy |
38,283
+10,515
| +38% | +$3.47M | 0.06% | 232 |
|
|
2015
Q2 | $11.2M | Buy |
27,768
+6,127
| +28% | +$2.46M | 0.06% | 263 |
|
|
2015
Q1 | $9.14M | Buy |
+21,641
| New | +$8.53M | 0.05% | 263 |
|
|
2014
Q4 | – | Sell |
-15,794
| Closed | -$5.11M | – | 1954 |
|
|
2014
Q3 | $5.22M | Buy |
15,794
+12,250
| +346% | +$4.04M | 0.04% | 405 |
|
|
2014
Q2 | $1.12M | Sell |
3,544
-2,705
| -43% | -$814K | 0.01% | 865 |
|
|
2014
Q1 | $1.91M | Buy |
6,249
+3,556
| +132% | +$1.13M | 0.02% | 633 |
|
|
2013
Q4 | $753K | Buy |
2,693
+2,371
| +736% | +$613K | ﹤0.01% | 955 |
|
|
2013
Q3 | $78K | Buy |
+322
| New | +$72.1K | ﹤0.01% | 1732 |
|
Other funds holding BIIB
Jefferies Group's BIIB Position: Q3 2022 in Review
Jefferies Group reduced its Biogen (BIIB) stake by 100% in Q3 2022, selling an estimated $12.2M and leaving 50 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1553.
Jefferies Group first reported a position in BIIB in Q3 2013 and has held it in 36 quarters since. The position peaked at $41.4M in Q3 2016. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Jefferies Group held 50 shares of Biogen worth $13.3K as of Q3 2022.
- Jefferies Group sold 57,549 Biogen shares in Q3 2022, an estimated $12.2M.
- Biogen made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1553 holding.
- Jefferies Group first reported a position in Biogen in Q3 2013 and has held it in 36 quarters since.
- Jefferies Group's Biogen position peaked at $41.4M in Q3 2016.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.